Condition: Mpox (Monkeypox) · Smallpox · Orthopoxvirus Infection · Sponsor: BioNTech SE
This is a randomized, double-blind, placebo-controlled study which aims to assess the safety, reactogenicity, and immunogenicity after one and two doses of BNT166a or placebo in healthy participants.
This description comes directly from the study's public registry record.
BioNTech clinical trials patient information · +49 6131 9084 · patients@biontech.de
Always discuss trial participation with your own doctor first.
| University of Kinshasa UNIKIN | Kinshasa, Democratic Republic of the Congo | Recruiting |
| Institute National de Recherche Biomedicale | Kinshasa, Democratic Republic of the Congo | Not Yet Recruiting |
| TASK Applied Science | Cape Town, South Africa | Recruiting |
| TREAD Research Pty Ltd | Cape Town, South Africa | Recruiting |
| Desmond Tutu Health Foundation Masiphumelele Clinic | Cape Town, South Africa | Recruiting |
| Perinatal HIV Research Unit | Johannesburg, South Africa | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07379580